Oncology – Gastrointestinal
RCT | Effectiveness of Etoposide and Cisplatin vs. Irinotecan and Cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system.
22 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
JCOG1213 (TOPIC NEC), the first randomized phase III trial in advanced neuroendocrine carcinoma of the digestive system, shows no significant difference in overall survival for etoposide+cisplatin versus irinotecan+cisplatin therapy https://t.co/JTELRlzTzi #GICSM pic.twitter.com/AQT8U4yd3l
— JAMA Oncology (@JAMAOnc) August 18, 2022
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
18 Aug, 2022 | 12:47h | UTCCommentaries:
Trastuzumab deruxtecan-related ILD/pneumonitis characterized – medwire News
Review | Barrett Esophagus.
17 Aug, 2022 | 14:26h | UTCBarrett Esophagus: A Review – JAMA (free for a limited period)
Audio clinical review: Barrett Esophagus – JAMA
M-A | Use of folic acid supplementation to halt and even reverse the progression of gastric precancerous conditions.
11 Aug, 2022 | 11:51h | UTCCommentary: Can Folic Acid Halt or Reverse Progression of Gastric Precancerous Conditions? – Medscape (free registration required)
RCT | Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma.
5 Aug, 2022 | 13:50h | UTCLenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Adding TACE to Lenvatinib Boosts Survival in Advanced Liver Cancer — In China-based trial, overall survival in first-line improved by 6 months versus lenvatinib alone – MedPage Today (free registration required)
Gastric cancer | ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
4 Aug, 2022 | 14:14h | UTC
Esophageal cancer | ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
4 Aug, 2022 | 14:12h | UTC
Mucinous rectal cancers: clinical features and prognosis in a population-based cohort.
4 Aug, 2022 | 13:17h | UTCMucinous rectal cancers: clinical features and prognosis in a population-based cohort – BJS Open
Commentary on Twitter
https://twitter.com/BjsOpen/status/1521784196255027201
M-A | Repeat hepatic resection vs. percutaneous ablation for the treatment of recurrent hepatocellular carcinoma.
4 Aug, 2022 | 13:27h | UTC
Commentary on Twitter
Recurrent #HCC after resection: re-resect or ablate?
📰#systematicreviewRedo-Resection has:
– ⏫Morbidity 17% vs 3%
– ⏫ recurrence free survival (HR 0.79)
– ⚖️ overall survival (HR 0.93 (0.83-1.04))https://t.co/WWwsHNkNQ9#SoMe4Surgery #some4hpb@SEIQuirurgica @asgbi pic.twitter.com/h4apdpY7eh— BJS Open (@BjsOpen) May 6, 2022
M-A | Endoscopic resection versus surgery in the treatment of early gastric cancer.
1 Aug, 2022 | 11:56h | UTC
Long-term results of a RCT | Active maintenance Olaparib vs. Placebo for germline BRCA-mutated metastatic pancreatic cancer.
29 Jul, 2022 | 12:18h | UTCOverall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
OS data from the POLO trial of maintenance olaparib vs placebo for pts with BRCA-mutant PDAC reveal no significant benefit (median 19.0 vs 19.2 months) although the curves separated at 24 months & 3-yr OS was 33.9% vs 17.8%; other outcomes favour olaparib: https://t.co/JZ28MsGV0B
— NatureRevClinOncol (@NatRevClinOncol) July 20, 2022
M-A | Toxicity profiles of systemic therapies for advanced hepatocellular carcinoma.
26 Jul, 2022 | 12:34h | UTC
Commentary on Twitter
This meta-analysis of 30 high-quality RCTs in patients with advanced hepatocellular carcinoma found that immune checkpoint inhibitors were associated with similar liver toxicity but lower serious adverse events compared to tyrosine kinase inhibitors. https://t.co/i0gJg0bqdX
— JAMA Network Open (@JAMANetworkOpen) July 18, 2022
RCT | Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer.
21 Jul, 2022 | 13:00h | UTCSee also: Visual Abstract
Commentary: Laparoscopy Noninferior to Open Surgery in Locally Advanced Gastric Cancer – MedPage Today (free registration required)
Related:
Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Phase 1b/2 RCT | Niraparib plus nivolumab vs. niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer.
20 Jul, 2022 | 11:39h | UTCNiraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/TheLancetOncol/status/1545362068026556418
Using circulating tumor DNA in colorectal cancer: current and evolving practices.
18 Jul, 2022 | 10:51h | UTC
Phase 2 RCT | Efficacy of preoperative mFOLFIRINOX vs. mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas.
15 Jul, 2022 | 12:29h | UTCEfficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the PancreasThe A021501 Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer – JAMA (free for a limited period)
Commentary on Twitter
Ph 2 trial of 126 pts w/borderline resectable pancreatic ductal adenoCa shows 18 mo OS after neoadjuvant mFOLFIRINOX of 66.7%, favorable vs. historical data; 18m OS if mFOLFORINOX then hypofract RT is 47.3%, if chemo then pancreatectomy is 87.5%. https://t.co/wOMNrTOAzm
— JAMA Oncology (@JAMAOnc) July 14, 2022
Randomized crossover trial | AI reduces miss rate of precancerous polyps in colorectal cancer screening.
14 Jul, 2022 | 12:29h | UTCNews Release: AI reduces miss rate of precancerous polyps in colorectal cancer screening – Mayo Clinic
Original Study: Impact of Artificial Intelligence on Miss Rate of Colorectal Neoplasia – Gastroenterology
M-A | Risk of developing gallbladder cancer in patients with gallbladder polyps detected on Trans-Abdominal ultrasound.
14 Jul, 2022 | 12:14h | UTCRisk of developing gallbladder cancer in patients with gallbladder polyps detected on Trans-Abdominal ultrasound: a systematic review and Meta-Analysis – British Journal of Radiology (link to abstract – $ for full-text)
Related:
Critical Analysis of the Updated Guidelines for Management of Gallbladder Polyps – Annals of Surgical Oncology (if the link is paywalled, try this one)
RCT | Cabozantinib plus atezolizumab vs. sorafenib for advanced hepatocellular carcinoma.
8 Jul, 2022 | 11:41h | UTCInvited Commentary: Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy – The Lancet Oncology (free registration required)
Commentary on Twitter
In the phase III COSMIC-312 trial in 837 pts with advanced-stage HCC, mPFS was 6.8 vs 4.2 months (HR 0.63; P=.0012) & mOS was 15.4 vs 15.5 months (HR 0.90; P=.44) with cabozantinib+atezolizumab vs sorafenib; mPFS with cabozantinib alone was 5.8 months: https://t.co/eiZEqSxLAr
— NatureRevClinOncol (@NatRevClinOncol) July 6, 2022
The multicenter cancer of pancreas screening study: impact on stage and survival.
5 Jul, 2022 | 11:46h | UTC
Commentary on Twitter
👀 The Cancer of Pancreas Screening (CAPS) program achieves early #PancreaticCancer detection and long-term survival with surveillance ➡️ https://t.co/flqUtSvkcg #JCO #pancSM @mggoggins pic.twitter.com/wj6DMXclVC
— Journal of Clinical Oncology (@JCO_ASCO) June 30, 2022
M-A | Risk factors of clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy.
5 Jul, 2022 | 11:32h | UTCUEG and EAES rapid guideline on transanal total mesorectal excision for rectal cancer.
1 Jul, 2022 | 11:33h | UTC
RCT: Oxaliplatin (3 months vs. 6 months) with 6 months of Fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer.
1 Jul, 2022 | 10:59h | UTC
RCT: The effect of enhanced recovery after minimally invasive esophagectomy.
1 Jul, 2022 | 10:56h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Visual abstract: ASO Visual Abstract: Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery—ERAS and Esophagectomy
Enhanced recovery after surgery (ERAS) programs for esophagectomy – Journal of Thoracic Disease
Systematic Review: Trastuzumab Deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies.
29 Jun, 2022 | 10:59h | UTC